Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Chubb
Daiichi Sankyo
Colorcon
Healthtrust
Dow
US Department of Justice
Boehringer Ingelheim
Cipla

Generated: May 21, 2018

DrugPatentWatch Database Preview

Details for Patent: 6,949,571

« Back to Dashboard

Which drugs does patent 6,949,571 protect, and when does it expire?

Patent 6,949,571 protects FYCOMPA and is included in two NDAs.

This patent has forty-six patent family members in twenty-six countries.
Summary for Patent: 6,949,571
Title: 1,2-dihydropyridine compounds, process for preparation of the same and use thereof
Abstract:The present invention provides a novel compound having an excellent AMPA receptor inhibitory action and/or kainate inhibitory action. A compound represented by the following formula, a salt thereof or hydrates thereof. ##STR1## In the formula, Q indicates NH, O or S; and R.sup.1, R.sup.2, R.sup.3, R.sup.4 and R.sup.5 are the same as or different from each other and each indicates hydrogen atom, a halogen atom, a C.sub.1-6 alkyl group or a group represented by the formula --X-A (wherein X indicates a single bond, an optionally substituted C.sub.1-6 alkylene group etc.; and A indicates an optionally substituted C.sub.6-14 aromatic hydrocarbocyclic group or 5- to 14-membered aromatic heterocyclic group etc.).
Inventor(s): Nagato; Satoshi (Chiba, JP), Ueno; Kohshi (Ibaraki, JP), Kawano; Koki (Ibaraki, JP), Norimine; Yoshihiko (Ibaraki, JP), Ito; Koichi (Chiba, JP), Hanada; Takahisa (Ibaraki, JP), Ueno; Masataka (Ibaraki, JP), Amino; Hiroyuki (Ibaraki, JP), Ogo; Makoto (Ibaraki, JP), Hatakeyama; Shinji (Ibaraki, JP), Groom; Anthony John (Wiltshire, GB), Rivers; Leanne (Kent, GB), Smith; Terence (Cambridgeshire, GB)
Assignee: Eisai Co., Ltd. (Tokyo, JP)
Application Number:10/296,719
Patent Claim Types:
see list of patent claims
Compound; Use; Composition;

Drugs Protected by US Patent 6,949,571

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Eisai Inc FYCOMPA perampanel SUSPENSION;ORAL 208277-001 Apr 29, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF PARTIAL-ONSET SEIZURES WITH OR WITHOUT SECONDARILY GENERALIZED SEIZURES IN PATIENTS WITH EPILEPSY ➤ Try a Free Trial
Eisai Inc FYCOMPA perampanel SUSPENSION;ORAL 208277-001 Apr 29, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY ➤ Try a Free Trial
Eisai Inc FYCOMPA perampanel SUSPENSION;ORAL 208277-001 Apr 29, 2016 RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF EPILEPSY ➤ Try a Free Trial
Eisai Inc FYCOMPA perampanel TABLET;ORAL 202834-001 Oct 22, 2012 RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial Y Y TREATMENT OF PRIMARY GENERALIZED TONIC-CLONIC SEIZURES AS ADJUNCTIVE THERAPY IN PATIENTS WITH EPILEPSY ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Foreign Priority and PCT Information for Patent: 6,949,571

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2000-175966Jun 12, 2000
United Kingdom0022483Sep 13, 2000
PCT Information
PCT FiledJune 08, 2001PCT Application Number:PCT/JP01/04857
PCT Publication Date:December 20, 2001PCT Publication Number: WO01/96308

Non-Orange Book US Patents Family Members for Patent 6,949,571

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,563,811 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof ➤ Try a Free Trial
7,939,549 1,2-dihydropyridine compounds, manufacturing method thereof and use thereof ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 6,949,571

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Austria 420862 ➤ Try a Free Trial
Australia 2001262723 ➤ Try a Free Trial
Australia 6272301 ➤ Try a Free Trial
Brazil 0111596 ➤ Try a Free Trial
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Fuji
Deloitte
Farmers Insurance
Argus Health
Chubb
Boehringer Ingelheim
Dow
Accenture
Chinese Patent Office

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.